Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: 11 February at 7:30:06 pm GMT+1 ...

At close: 7 February at 3:56:17 pm GMT-5 ...

Lucid Group (NASDAQ: LCID) looks expensive on multiple metrics. Shares trade at 9.1 times sales, despite the company never reaching profitability. Last quarter, its gross profit margins was deeply ...

Lucid Group stock looks expensive on some metrics. However, this year's results could change everything. But valuations are typically forward-looking, not backwards-looking. And when you hear what ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...